Alzheimer disease: Neuropsychology and pharmacology/ (Record no. 190172)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07310nam a2200157Ia 4500 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 987654321 |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | CUS |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.831061 |
| Item number | EMI/A |
| 245 #0 - TITLE STATEMENT | |
| Title | Alzheimer disease: Neuropsychology and pharmacology/ |
| Statement of responsibility, etc. | Emilien, Gerad |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc. | Boston: |
| Name of publisher, distributor, etc. | Birkhauser Verlag, |
| Date of publication, distribution, etc. | 2003. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 288 p. |
| 505 ## - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Part I: Biological correlates of Alzheimer disease<br/>Alzheimer disease<br/>Introduction ..<br/>Differential diagnosis<br/>Alzheimer versus frontotemporal dementias .<br/>Semantic dementia<br/>Alzheimer versus dementia with Lewy bodies<br/>Epidemiology<br/>Risk factors ...<br/>Smoking history<br/>Sex<br/>Head trauma ...<br/>Cardiovascular risk factors ....<br/>Psychiatric manifestations<br/>Genetic susceptibility factors ..<br/>Herpes simplex virus infections<br/>Assessing outcome<br/>Discussion ..<br/>Neurological dysfunctions in Alzheimer disease<br/>Introduction .<br/>Neurochemical studies<br/>Senile plaques and neurofibrillary tangles .<br/>The p-amyloid precursor protein<br/>The amyloid cascade hypothesis..<br/>Selective vulnerability..<br/>Electrophysiological and imaging studies<br/>Magnetic resonance imaging<br/>Positron emission tomography ...<br/>Magnetization transfer ratio<br/>Discussion<br/>Pharmacology of Alzheimer disease<br/>Introduction<br/>Cholinergic receptors<br/>Cholinergic receptors and Ap deposition<br/>Monoaminergic receptors<br/>Serotonin<br/>Serotonin depletion studies....<br/>Serotonin transporter<br/>Serotonin-cholinergic interaction<br/>Serotonin receptors and psychotic symptoms.<br/>Noradrenaline<br/>Noradrenergic-cholinergic interactions<br/>Dopamine<br/>Glutamate and NMDA receptors<br/>The cytokines<br/>Cyclo-oxygenase enzymes<br/>Metal-mediated oxy-radical and peroxide formation<br/>Neuroinflammation<br/>Oxidative stress<br/>Ap and endoplasmic reticulum-associated binding protein.<br/>A neurochemical marker for preclinical Alzheimer disease?<br/>CSF tau<br/>CSF cytokines<br/>Choline acetyltransferase activity<br/>Isoprostanes<br/>Calcium<br/>Serum anti-amyloid peptide antibodies<br/>Discussion<br/>Chapter 4:<br/>Molecular genetics of Alzheimer disease<br/>introduction<br/>Early onset Alzheimer disease .<br/>PS1 gene<br/>PS2 gene<br/>APP gene<br/>Interleukin genes<br/>Late-onset Alzheimer disease.<br/>Apolipoprotein E gene.<br/>Alpha-2 macroglobulin<br/>Tau immunoreactivities<br/>Genetic testing for Alzheimer disectse susceptibility<br/>Ethnic and racial differences...<br/>Discussion ..<br/>Promises of animal models of Alzheimer disease<br/>Introduction ..<br/>Transgenic models of mutant human (Hu) APR<br/>with Ap amyloid deposition .<br/>The Games mice..<br/>The Hsiao mice ...<br/>The Novartis mice<br/>The CT100 mice ..<br/>Mutant presenilin mice ..<br/>Hu APP over-expression on the ApoE null background ..<br/>Hu APP over-expression combined with oxidative stress.<br/>APP knockout mice<br/>PS1 knockout mice<br/>Immunization with Ap..<br/>Discussion<br/>Part II: Neuropsychoiogy of Alzheimer disease<br/>What is memory?<br/>Introduction<br/>Short-term memory, working memory and long-term memory<br/>Short-term memory<br/>Working memory<br/>The central executive system<br/>The phonological loop<br/>The visuospatial sketchpad ..<br/>The episodic buffer.<br/>Long-term memory.<br/>Declarative memory<br/>Episodic memory<br/>Semantic memory<br/>Autobiographical memory...<br/>Prospective memory<br/>Procedural memory.<br/>Skill learning<br/>Repetition priming.<br/>Controlled and automatic memory process.<br/>Neuroanatomy and physiology of memory.<br/>Medial-temporal and diencephalic systems.<br/>The amygdala<br/>The hippocampus<br/>The frontal lobes<br/>Amnesia<br/>Mental imaging<br/>Memory alterations in aging<br/>Discussion .<br/>Mild cognitive impairment<br/>Introduction<br/>Boundary between normal aging and MCl<br/>Neuropsychoiogical markers<br/>Eyeblink classical conditioning<br/>A standardized clinical assessment?<br/>Discussion<br/>ve impairment in Alzheimer disease<br/>Introduction<br/>Cognitive impairments..<br/>Executive function<br/>Working memory deficit<br/>Episodic memory deficit<br/>Semantic memory deficit<br/>Naming deficit<br/>Intrusion errors<br/>Visuo-spatial deficit<br/>Language<br/>Memory distortions<br/>Implicit memory performance<br/>Cognitive differences in neurodegenerative disorders<br/>Typical Alzheimer disease.<br/>Frontotemporal dementia<br/>Semantic dementia<br/>Lewy body dementia<br/>Discussion<br/>oral and psychological impairments<br/>Introduction<br/>Psychological impairment.<br/>Anxiety<br/>Agitation and aggression ...<br/>Depression<br/>Psychosis<br/>Sexual impairment .<br/>Delirium<br/>Sleep disturbances..<br/>Wandering<br/>Apathy..<br/>Alterations in dietary habit.<br/>Discussion .<br/>Chapter 10:<br/>Assessment of memory<br/>Introduction<br/>Memory assessment<br/>The Alzheimer Disease Assessment Scale - Cognitive Subscale ...<br/>The Mini-Mental State Examination,<br/>The Blessed Dementia Scale<br/>The Gottfries-Brane-Steen Scale<br/>The Cambridge Mental Disorders of the Elderly Examination<br/>The 7-minute neurocognitive screening battery....<br/>The Mattis dementia rating scale.<br/>The Brown-Peterson task<br/>The Cognitive Drug Research Computerized Assessment System<br/>Informant report questionnaire<br/>Choice of an appropriate sensitive cognitive test.<br/>Discussion .<br/>Chapter 11:<br/>Functional abilities and behavioral symptom assessments<br/>Introduction<br/>Functional abilities and activities of daily living assessment<br/>Blessed-Roth dementia scale<br/>Progressive deterioration scale<br/>Interview for deterioration in daily living activities in dementia..<br/>AD Cooperative study-activities of daily living inventory<br/>Alzheimer disease functional assessment and change scale<br/>Disability assessment for dementia<br/>Behavioral assessment<br/>The dementia behavior disturbance<br/>The eating behavior scale<br/>Neuropsychiatric inventory<br/>Behavioral pathology in Alzheimer disease rating scale<br/>The Committee of the Consortium to establish a registry for<br/>Alzheimer disease<br/>The MOUSEPAD<br/>The Cohen-Mansfield agitation inventory.<br/>The geriatric mental state schedule<br/>The geriatric depression scale<br/>I The Cornell scale<br/>The consortium to establish a registry for AD behavior rating<br/>scale for dementia<br/>Global function assessment<br/>The clinical dementia rating scale<br/>The global interview-based change scale.<br/>The global deterioration scale<br/>AD cooperative study clinical global impression of change.<br/>Clinician's global impression of change<br/>Quality of life<br/>Concept of utilities.<br/>Discussion<br/>Part III: Treatment of Alzheimer disease<br/>Pharmacological treatments of cognitive deficits<br/>Introduction<br/>Modulation of the cholinergic system<br/>Tacrine<br/>Donepezil.<br/>Rivastigmine<br/>Metrifonate.<br/>Galantamine.<br/>Controlled-release physostigmine<br/>Nicotinic cholinergic strategies<br/>Modulation of other neurotransmitter systems..<br/>Neurotrophic growth factors<br/>Decreasing the cellular reaction to neurodegeneration<br/>Propentofylline<br/>Drugs that reduce oxidative stress.<br/>Estrogen replacement therapy<br/>Therapeutic strategies in the APP/Ab amyloidgenic pathway<br/>Anti-inflammatory drugs<br/>Modulation of cholesterol homeostasis.<br/>Metal ion chelators<br/>The emerging field of pharmacogenetics<br/>Discussion<br/>Chapter 13:<br/>Pharmacological treatment of neuropsychiatric symptoms<br/>Introduction<br/>Depression..<br/>Psychosis....<br/>Anxiety<br/>Discussion ..<br/>Chapter 14:<br/>Psychological support and cognitive rehabilitation<br/>Introduction<br/>Cognitive rehabilitation<br/>Domain-specific knowledge —<br/>Errorless learning<br/>Action-based memory..<br/>Reality orientation<br/>Metacognition improvement...<br/>Spaced retrieval<br/>Some other forms of treatment<br/>Imagery mnemonics.<br/>External aids.<br/>Discussion ...<br/>Chapter 15:<br/>Discussion and conclusion . |
| 650 ## - SUBJECT | |
| Keyword | Alzheimer's disease |
| 650 ## - SUBJECT | |
| Keyword | Chemotherapy |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | General Books |
| Withdrawn status | Lost status | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Full call number | Accession number | Date last seen | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Central Library, Sikkim University | Central Library, Sikkim University | General Book Section | 15/09/2016 | 616.831061 EMI/A | 44799 | 15/09/2016 | General Books |